"Pharmaceutical headline king" the third batch of national harvest hanging network! Several more provinces have announced.

(2020/09/22) High-value consumables national volume procurement on the pharmaceutical industry's 3 major impact; 323 A-share listed companies during the year to implement repurchase pharmaceutical and biological enterprises to buy back more than 6 billion yuan cumulatively; domestic anti-cancer new drugs approved for listing increased by 125% YoY to force MNC Hengrui, Baiji and other hit ... (Click on the title to get the original text) "Pharmaceutical 1st Time" The European Union issued a number of positive comments on drug reviews involving AZ/Mercadon Lynparza ... On September 21st the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) issued a number of positive comments on drug reviews, recommending approval in the European Union of AstraZeneza/Merca East Lynparza (olaparib) combined beva monoantigen for first-line maintenance therapy for patients with ovarian cancer with erotic recombinant defect (HRD) positive, Roche anti-PD-L1 therapy Tecentriq (atezolizumab, art-pearl monoantigen) in the form of avastin (bevacizumab, beva monoantigen) for the treatment of adult patients with non-extinable or metastatic hepatocellular carcinoma (HCC) who have not previously received systematic treatment, as well as the new 100 mg/mL intravenous injection (IV) formula from Alexion company ULTOMIRIS®
: The European Commission usually makes approval decisions within about two months of CHMP's recommendations.
"Pharmaceutical Rubik's Cube" high-value consumables national belt procurement on the pharmaceutical industry 3 major impact due to the relatively high unit price and resource ratio, high-value medical supplies have been the focus of various provinces and cities of the governance object.
as a favorable means of squeezing virtual high moisture, with volume procurement has always been the main way for each province to deal with high-value consumables.
The State Health Insurance Administration, together with the relevant departments, recently held a national organization in Tianjin high-value medical supplies centralized procurement and use of the work of the start of the work to convey an important signal, will be the crown vein stent as the beginning, high-value medical supplies national collection will enter the full implementation phase on January 1, 2021.
According to the schedule announced by Zhang Tiejun, deputy director of The Tianjin Medical Insurance Bureau, it is expected that in September, all coalition medical institutions will be organized to complete the reporting and statistics of historical usage and future demand;
, what will be the impact of high-value medical supplies? What are the issues that deserve attention? Combing the relevant information found that there are three main effects.
: Can I copy the low-cost purchase of medicines? "Pharmaceutical representative" the third batch of national harvest hanging network! Several provinces have announced Hebei, Heilongjiang, Qinghai... Recently, Hebei, Heilongjiang, Qinghai, Jiangxi, Hubei, Yunnan, Guangdong, the seven provinces have also issued a notice.
: will be completed this month, the network declaration, distribution association.
During the year, 323 A-share listed companies implemented repurchases of more than 6 billion yuan of shares of pharmaceutical and biological enterprises, which refers to the act of listed companies buying back shares of the company issued or flowing outside the company through certain procedures, as a defensive behavior of listed companies to change their capital structure when their share prices are undervalued, the main purpose of which is to maintain the stability of the company's share price.
: Share buybacks can reduce the number of shares outstanding outside listed companies.
"E drug manager" domestic anti-cancer new drugs approved for market year-on-year increase of 125% forced flat MNC Hengrui, Baiji and other hit as of September 10, 2020 a total of 9 domestic anti-tumor new drugs were approved for the market, MNC new drugs approved 10 varieties.
the number of new drugs should see changes in growth, with domestic new drugs up 125% year-on-year and MNC down 9%.
, the proportion of new domestic drugs has been close to 50%.
: Is the era of domestic innovation really coming?